Table 3 Awareness and management protocol according to prior MRONJ experience
Sex | MRONJ experience | Pa | |
|---|---|---|---|
No | Yes | ||
Male | 541 (76.5%) | 246 (84.0%) | 0.009 |
Female | 166 (23.5%) | 47 (16.0%) | |
Age (y) | |||
≤ 30 | 5 (0.7%) | 27 (9.2%) | < 0.0001 |
31–40 | 226 (32%) | 72 (24.6%) | |
41–50 | 350 (49.5%) | 116 (39.6%) | |
51–60 | 102 (14.4%) | 70 (23.9%) | |
≥ 61 | 24 (3.4%) | 8 (2.7%) | |
Type of practice | |||
Private clinicb | 605 (85.6%) | 248 (84.6%) | 0.705 |
Non-private clinicc | 102 (14.4%) | 45 (15.4%) | |
Clinical experience (y) | |||
≤ 5 | 64 (9.1%) | 38 (13%) | 0.030 |
6–10 | 135 (19.1%) | 44 (15%) | |
11–15 | 193 (27.3%) | 63 (21.5%) | |
16–20 | 150 (21.2%) | 62 (21.2%) | |
≥ 21 | 165 (23.3%) | 86 (29.4%) | |
Do you record if the patient is taking anti-osteoporotic drugs? | |||
Yes | 689 (97.5%) | 280 (95.6%) | 0.116 |
No | 18 (2.5%) | 13 (4.4%) | |
Do you record the name of the drug and duration of its use? | |||
No | 115 (16.3%) | 72 (24.6%) | 0.007 |
Name only | 115 (16.3%) | 48 (16.4%) | |
Name and duration | 477 (67.5%) | 173 (59.0%) | |
Do you ask for a doctor's referral letter prior to dental surgery procedures? | |||
Yes | 423 (59.8%) | 168 (57.3%) | 0.466 |
No | 284 (40.2%) | 125 (42.7%) | |
How long do you advise patients to discontinue the anti-osteoporotic agent before tooth extraction or implant placement? | |||
≤ 2 months | 88 (12.4%) | 61 (20.8%) | 0.001 |
3–5 months | 321 (45.4%) | 136 (46.4%) | |
≥ 6 months | 298 (42.1%) | 96 (32.8%) | |
Do you recommend different drug holidays depending on the type of drug (bisphosphonates, denosumab, SERMs, PTH)? | |||
Yes | 319 (45.1%) | 148 (50.5%) | 0.120 |
No | 388 (54.9%) | 145 (49.5%) | |
If you have encountered case/s of MRONJ, what type of medication caused it? | |||
Bisphosphonates | – | 276 (94.2%) | – |
Denosumab | – | 13 (4.4%) | |
SERMs | – | 4 (1.4%) | |
No experience | 707 (100.0%) | – | |